Literature DB >> 11023108

Tubulocystic clear cell adenocarcinoma arising within the prostate.

C C Pan1, H Chiang, Y H Chang, J I Epstein.   

Abstract

Neoplasms resembling ovarian common epithelial-type tumors, including clear cell adenocarcinomas, rarely occur in the lower urinary tract of men. When they do, they develop in the urethra or urinary bladder. We report a case of such a tumor arising within the prostate of a 47-year-old man. The tumor was a cystic mass in the left posterolateral region of the prostate. Histologically, the tumor was chiefly composed of tubulocystic and papillary glands lined by glycogen-rich, cuboidal or hobnail cells with clear to eosinophilic cytoplasm. The tumor cells were strongly positive for pan-cytokeratin, low molecular weight cytokeratin, and epithelial membrane antigen, and focally positive for high molecular weight keratin. The tumor did not immunohistochemically express prostate-specific antigen (PSA) and prostatic acid phosphatase. Serologically, the patient had increased levels of CA125 instead of PSA. The clinical as well as the pathologic features are consistent with a clear cell adenocarcinoma as seen in the female genital tract rather than a typical prostatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023108     DOI: 10.1097/00000478-200010000-00016

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  Current practice of Gleason grading of prostate carcinoma.

Authors:  Antonio Lopez-Beltran; Gregor Mikuz; Rafael J Luque; Roberta Mazzucchelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2005-11-23       Impact factor: 4.064

2.  Renal type clear cell carcinoma of the prostate: a diagnostic dilemma.

Authors:  Harish S Permi; Kishan Prasad Hosapatna Laxminarayana; Sunil Kumar Yeshvanth; Jayaprakash K Shetty
Journal:  J Lab Physicians       Date:  2011-07

3.  Renal-type clear cell carcinoma of the prostate: A case report.

Authors:  Qiulan Wang; Yongjie Xue
Journal:  Oncol Lett       Date:  2015-03-20       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.